Fielding Lapses in Kanpur Show Why Uttar Pradesh Cannot Rely Solely on Batting Power 
Ashok Leyland share price jumps 11.65% on 23% rise in October CV sales 
Afghanistan beat Zimbabwe in Sharjah: 72-run Test win seals 1-0 series, T20I win by seven wickets 
Sensex surges 1,600 points as oil slides after U.S. midterm results lift risk appetite 
Doncic scores 40 as Lakers beat Kings 116-103 at Golden 1 Center 
CUHK Celebrates Students’ Positive Contributions to the World
HONG KONG SAR - Media OutReach - 24 October 2023 - Ranked 47th in the World and 6th in Asia,...
Nagoya Anesthesia Clinic Initiates Inbound Medical Treatment for Treatment-Resistant Depression and Intractable Chronic Pain Using Ketamine
NAGOYA, Japan--(BUSINESS WIRE)--Nagoya Anesthesia Clinic (https://nagoyamasui.com/), located in Nagoya City, Aichi Prefecture, Japan, has commenced inbound medical treatment for treatment-resistant...
Starlight Centre announces the launch and open house for their new after-school care centre for children with autism
Specifically aimed at autistic children in Pathlight and mainstream primary schools SINGAPORE - Media OutReach - 24 Oct 2023 -...
Quectel announces packed program of products and demos at KES 2023
SEOUL, South Korea--(BUSINESS WIRE)--Korean Electronics Show, Seoul: Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce its...
Spackman Media Group Artist Wi Ha-jun Stars in New Romance K-Drama Graduation & Reprises Role in SQUID GAME SEASON 2
Spackman Media Group artist Wi Ha-jun will headline a new romance K-drama, GRADUATION, directed by Ahn Pan-seok, who previously collaborated...
Smartsheet Invests in Australia-based Data Hosting to Better Serve Global Customer Base
The enterprise work management leader’s newest regional deployment will provide customers the ability to host their data onshore in Australia,...
Fabrinet to Announce First Quarter Fiscal Year 2024 Financial Results on November 6, 2023
BANGKOK--(BUSINESS WIRE)--Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to...
Gold Resource Corporation Announces Q3 2023 Conference Call
DENVER--(BUSINESS WIRE)--Gold Resource Corporation (NYSE American: GORO) (the “Companyâ€) will host a conference call Friday, November 3, 2023 at 10:00...
Polaris and OrionVM Partner to Next-Gen Cloud Transform Queensland ICT Market
OrionVM’s MicroPoP Technology Enables Leading Australian Data Centre to Uniquely Underpin Cloud Workloads, Including Enterprise Cloud, AI and Storage Solutions...
New Chinese Restrictions on Supply of Natural Graphite Will Negatively Impact Batteries Used in EV Market
Westwater Resources Offers Domestic Alternatives CENTENNIAL, Colo.--(BUSINESS WIRE)--Westwater Resources, Inc. (NYSE: American: WWR), an energy technology and battery-grade natural graphite...
Nanban Ventures Sends Letter Highlighting Steps Being Taken to Protect Investors
DALLAS--(BUSINESS WIRE)--Nanban Ventures LLC (“Nanban Venturesâ€), a Dallas-based venture capital firm investing in startups and other private companies that are...
Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor (TKI) at the European Society for Clinical Oncology (ESMO) Congress
BEIJING--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd. (“Avistone†or “the Companyâ€), a clinical-stage biotechnology company focused on precision oncology therapeutics, announced preliminary...
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months...
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and...
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median...
